

Development of a next generation immune checkpoint modulator towards the clinic; a humanized BTN3A antibody (ICT01) activating gamma9delta2 T cells

ImCheck Therapeutics is advancing the first activating butyrophilin BTN3A (CD277) antibody towards the clinic. The humanized antibody to BTN3A, ICT01, specifically activates human gamma9delta2 T-cells in-vitro and in-vivo and is planned to enter phase I studies early 2020. Additionally, therapeutic antibodies against 5 novel butyrophilins are currently validated. This opens a completely new space clearly different from the current B7/CD28 superfamily targets and has the potential to become the next generation immune checkpoint modulators.

Keywords : Immunotherapy, Immuno-oncology, Antibody, Immune checkpoint

Authors :

References : , , ,

Authors

René HOET 1,

1. R&D, Imcheck Therapeutics, MARSEILLE, FRANCE